Shares

40 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$2.88 - $4.8 $9,835 - $16,392
-3,415 Reduced 47.28%
3,808 $12,000
Q3 2023

Nov 14, 2023

BUY
$5.07 - $8.44 $5,566 - $9,267
1,098 Added 17.93%
7,223 $39,000
Q2 2023

Aug 10, 2023

BUY
$6.19 - $8.78 $5,069 - $7,190
819 Added 15.44%
6,125 $41,000
Q1 2023

May 15, 2023

SELL
$7.8 - $10.11 $11,356 - $14,720
-1,456 Reduced 21.53%
5,306 $46,000
Q4 2022

Jun 14, 2023

BUY
$6.26 - $9.34 $9,114 - $13,599
1,456 Added 27.44%
6,762 $51.7 Million
Q3 2022

Jun 14, 2023

BUY
$6.5 - $12.67 $9,464 - $18,447
1,456 Added 27.44%
6,762 $48.1 Million
Q2 2022

Jun 20, 2023

BUY
$6.4 - $14.73 $9,318 - $21,446
1,456 Added 27.44%
6,762 $54,000
Q2 2022

Mar 30, 2023

BUY
$6.4 - $14.73 $486 - $1,119
76 Added 1.14%
6,762 $54,000
Q2 2022

Aug 11, 2022

BUY
$6.4 - $14.73 $43,276 - $99,604
6,762 New
6,762 $55,000
Q1 2022

May 12, 2022

SELL
$10.12 - $28.9 $67,662 - $193,225
-6,686 Closed
0 $0
Q4 2021

Jun 21, 2023

BUY
$25.17 - $36.85 $34,734 - $50,853
1,380 Added 26.01%
6,686 $187,000
Q4 2021

Mar 30, 2023

BUY
$25.17 - $36.85 $4,681 - $6,854
186 Added 2.86%
6,686 $187,000
Q4 2021

Feb 15, 2022

BUY
$25.17 - $36.85 $4,681 - $6,854
186 Added 2.86%
6,686 $188,000
Q3 2021

Jun 21, 2023

BUY
$30.02 - $39.87 $42,898 - $56,974
1,429 Added 26.93%
6,735 $228,000
Q3 2021

Mar 30, 2023

SELL
$30.02 - $39.87 $13,779 - $18,300
-459 Reduced 6.6%
6,500 $220,000
Q3 2021

Nov 15, 2021

SELL
$30.02 - $39.87 $13,779 - $18,300
-459 Reduced 6.6%
6,500 $221,000
Q2 2021

Jun 21, 2023

BUY
$32.22 - $44.59 $53,259 - $73,707
1,653 Added 31.15%
6,959 $284,000
Q2 2021

Mar 30, 2023

BUY
$32.22 - $44.59 $45,720 - $63,273
1,419 Added 25.61%
6,959 $284,000
Q2 2021

Aug 16, 2021

BUY
$32.22 - $44.59 $224,025 - $310,034
6,953 Added 115883.33%
6,959 $284,000
Q1 2021

Jun 26, 2023

BUY
$37.26 - $67.74 $8,718 - $15,851
234 Added 4.41%
5,540 $223 Million
Q1 2021

Mar 30, 2023

SELL
$37.26 - $67.74 $9,277 - $16,867
-249 Reduced 4.3%
5,540 $223,000
Q1 2021

May 14, 2021

SELL
$37.26 - $67.74 $215,474 - $391,740
-5,783 Reduced 99.9%
6 $223,000
Q4 2020

Jun 22, 2023

BUY
$45.01 - $65.47 $21,739 - $31,622
483 Added 9.1%
5,789 $342,000
Q4 2020

Mar 30, 2023

SELL
$45.01 - $65.47 $5,086 - $7,398
-113 Reduced 1.91%
5,789 $342,000
Q4 2020

Feb 16, 2021

SELL
$45.01 - $65.47 $5,086 - $7,398
-113 Reduced 1.91%
5,789 $342,000
Q3 2020

Jun 26, 2023

BUY
$35.79 - $48.81 $21,330 - $29,090
596 Added 11.23%
5,902 $287,000
Q3 2020

Mar 30, 2023

BUY
$35.79 - $48.81 $9,019 - $12,300
252 Added 4.46%
5,902 $287,000
Q3 2020

Nov 13, 2020

BUY
$35.79 - $48.81 $9,019 - $12,300
252 Added 4.46%
5,902 $287,000
Q2 2020

Jun 26, 2023

BUY
$24.95 - $48.38 $8,582 - $16,642
344 Added 6.48%
5,650 $273,000
Q2 2020

Mar 30, 2023

BUY
$24.95 - $48.38 $46,431 - $90,035
1,861 Added 49.12%
5,650 $273,000
Q2 2020

Aug 14, 2020

BUY
$24.95 - $48.38 $46,431 - $90,035
1,861 Added 49.12%
5,650 $273,000
Q1 2020

Jul 12, 2023

SELL
$16.96 - $34.16 $25,728 - $51,820
-1,517 Reduced 28.59%
3,789 $105,000
Q1 2020

Mar 30, 2023

BUY
$16.96 - $34.16 $47,996 - $96,672
2,830 Added 295.1%
3,789 $105,000
Q1 2020

May 15, 2020

BUY
$16.96 - $34.16 $47,996 - $96,672
2,830 Added 295.1%
3,789 $105,000
Q4 2019

Jul 12, 2023

SELL
$24.56 - $32.8 $106,762 - $142,581
-4,347 Reduced 81.93%
959 $28,000
Q4 2019

Mar 30, 2023

SELL
$24.56 - $32.8 $368 - $491
-15 Reduced 1.54%
959 $28,000
Q4 2019

Feb 14, 2020

SELL
$24.56 - $32.8 $368 - $491
-15 Reduced 1.54%
959 $29,000
Q3 2019

Jul 12, 2023

SELL
$30.31 - $53.51 $131,302 - $231,805
-4,332 Reduced 81.64%
974 $30,000
Q3 2019

Mar 30, 2023

SELL
$30.31 - $53.51 $175,434 - $309,715
-5,788 Reduced 85.6%
974 $30,000
Q3 2019

Nov 14, 2019

BUY
$30.31 - $53.51 $29,521 - $52,118
974 New
974 $30,000

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $1.05B
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.